AssuredPartners Investment Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.62M Sell
6,352
-610
-9% -$623K 0.74% 32
2026
Q1
$6.45M Buy
6,962
+4,848
+229% +$4.91M 0.7% 34
2025
Q4
$2.27M Buy
2,114
+34
+2% +$32.5K 0.34% 73
2025
Q3
$1.59M Sell
2,080
-13
-0.6% -$9.67K 0.35% 52
2025
Q2
$1.63M Sell
2,093
-210
-9% -$163K 0.4% 50
2025
Q1
$1.9M Buy
2,303
+253
+12% +$211K 0.37% 75
2024
Q4
$1.58M Buy
+2,050
New +$1.7M 0.31% 88

Other funds holding LLY

AssuredPartners Investment Advisors's LLY Position: Q2 2026 in Review

AssuredPartners Investment Advisors reduced its Eli Lilly (LLY) stake by 8.8% in Q2 2026, selling an estimated $623K and leaving 6,352 shares worth $7.62M. The position accounts for 0.74% of the portfolio, ranked #32.

AssuredPartners Investment Advisors first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • AssuredPartners Investment Advisors held 6,352 shares of Eli Lilly worth $7.62M as of Q2 2026.
  • AssuredPartners Investment Advisors sold 610 Eli Lilly shares in Q2 2026, an estimated $623K.
  • Eli Lilly made up 0.74% of AssuredPartners Investment Advisors's portfolio in Q2 2026, its #32 holding.
  • AssuredPartners Investment Advisors first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on AssuredPartners Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.